Swi1 Inhibitors
Chemical inhibitors of Swi1 can act through various biochemical pathways to impede its function. Trichostatin A, for instance, inhibits histone deacetylase, leading to increased acetylation of histones which can alter chromatin structure and reduce the accessibility of transcription factors necessary for Swi1 function. Similarly, 5-Fluorouracil, by being metabolized into nucleotide analogs that integrate into RNA and DNA, disrupts nucleic acid synthesis and function, crucial for the transcription factors that regulate Swi1. Camptothecin and Etoposide target topoisomerases I and II, respectively, which are fundamental for DNA replication and transcription processes, thereby interfering with the transcriptional machinery upon which Swi1 relies. Mitomycin C induces DNA cross-links that can obstruct transcription and replication pathways, affecting Swi1's activity.
In a parallel mechanism, Bortezomib and MG132, both proteasome inhibitors, can result in the accumulation of misfolded proteins, inducing cellular stress and potentially disrupting protein interactions and signaling pathways that involve Swi1. Cycloheximide, by inhibiting protein synthesis, can decrease the levels of proteins that interact with or regulate Swi1, impacting its activity. Rapamycin, an mTOR inhibitor, and PI3K inhibitors LY294002 and Wortmannin can disrupt signaling pathways essential for Swi1 function, as mTOR and PI3K/AKT pathways are critical for cellular growth and proliferation, which are processes where Swi1 exerts effects. Finally, Staurosporine, a non-selective kinase inhibitor, can inhibit kinases responsible for phosphorylating proteins that regulate or interact with Swi1, which in turn could lead to the inhibition of Swi1's role in cellular signaling pathways. Each of these chemicals, by targeting a specific cellular process or signaling pathway, can contribute to the functional inhibition of Swi1.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A inhibits histone deacetylase (HDAC), which can increase acetylation levels of histones, thereby affecting chromatin structure and potentially reducing the accessibility of transcription factors to genes that are required for Swi1 function. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
5-Fluorouracil is metabolized to nucleotide analogs that can be incorporated into RNA and DNA, disrupting the synthesis and function of nucleic acids, which are crucial for the transcription factors and other DNA-binding proteins that regulate Swi1 activity. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin inhibits topoisomerase I, which is essential for DNA replication and transcription. Inhibition of topoisomerase I could lead to DNA damage and interfere with the transcriptional machinery that controls Swi1 expression and function. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide targets topoisomerase II, which can lead to DNA breaks and interfere with the processes required for Swi1 to exert its functions, such as transcription regulation and DNA repair. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Mitomycin C forms DNA adducts and cross-links, which can impede transcriptional processes and replication that are necessary for Swi1 activity and its associated pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of misfolded proteins, inducing cellular stress and potentially disrupting protein interactions and signaling pathways involving Swi1. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is another proteasome inhibitor that can increase cellular stress and interfere with the degradation of regulatory proteins that control Swi1 activity. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with the translocation step in elongation on the ribosome, which can decrease the levels of proteins that interact with or regulate Swi1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR, a kinase that regulates cell growth and proliferation. By inhibiting mTOR, it can disrupt signaling pathways that are necessary for Swi1 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which can downregulate AKT signaling, and consequently, may disrupt downstream signaling pathways that are involved in the regulation of Swi1 activity. | ||||||